about
Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactionsAdvances in Antibody DesignIntrahippocampal administration of a domain antibody that binds aggregated amyloid-β reverses cognitive deficits produced by diet-induced obesity.High-throughput analysis of concentration-dependent antibody self-association.Modulation of curli assembly and pellicle biofilm formation by chemical and protein chaperones.Structure-based design of conformation- and sequence-specific antibodies against amyloid β.Unraveling infectious structures, strain variants and species barriers for the yeast prion [PSI+].Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies.Engineered Autonomous Human Variable DomainsRational design of potent domain antibody inhibitors of amyloid fibril assembly.Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid PolypeptideMechanisms of transthyretin inhibition of β-amyloid aggregation in vitro.Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability.High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.Site-specific structural analysis of a yeast prion strain with species-specific seeding activity.An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies.Prion recognition elements govern nucleation, strain specificity and species barriers.Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathwaysResveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformersPolyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β.Lifting the veil on amyloid drug design.Predictive crystallization of ribonuclease A via rapid screening of osmotic second virial coefficients.Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions.Facile Preparation of Stable Antibody-Gold Conjugates and Application to Affinity-Capture Self-Interaction Nanoparticle Spectroscopy.Comparison of Human and Bovine Insulin Amyloidogenesis under Uniform Shear.Biophysical and Sequence-Based Methods for Identifying Monovalent and Bivalent Antibodies with High Colloidal Stability.Biospecific protein immobilization for rapid analysis of weak protein interactions using self-interaction nanoparticle spectroscopy.Self-interaction nanoparticle spectroscopy: a nanoparticle-based protein interaction assay.High-throughput assay for measuring monoclonal antibody self-association and aggregation in serum.Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates.Measurements of Monoclonal Antibody Self-Association Are Correlated with Complex Biophysical Properties.Correlation of diafiltration sieving behavior of lysozyme-BSA mixtures with osmotic second virial cross-coefficients.Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy.Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process.Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold.Self-interaction chromatography: a novel screening method for rational protein crystallizationRemoval versus fragmentation of amyloid-forming precursors via membrane filtrationSolution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strengthPolyphenolic disaccharides endow proteins with unusual resistance to aggregationAggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions
P50
Q27002558-9FBCE1D5-FBEF-4092-9748-7584EB6002F8Q28817608-6AB068DC-36F2-43BC-98C2-F6960BEC4AC4Q30277159-DE929289-5F19-4799-BB50-A771FBCBF2A4Q30462680-40F7369C-7B3C-4DD6-B63E-D28EEFE9AD30Q34570711-07DA995B-6B5B-44A4-99BE-C6A94E063B3AQ35657526-F3CEA62A-278A-4BAD-9DA9-426417A5EA40Q35852028-74671FCF-CE77-4684-BBA5-A8596E99F1D1Q36130672-75B8439B-3A41-4BC7-B53D-5AA12FFEA701Q36140177-D8BC4647-CE71-4957-82CC-C936D2DF48C7Q36471297-814F5A95-60FD-4892-898B-8FD65EA8B28EQ36548388-FC92C436-7BFD-4639-96E3-12B5C62FCC34Q37381796-23CE28AA-1B16-48CE-94CA-CB1E03633989Q37724050-E2699BAB-9DA9-4462-BDC0-800A3454045DQ38718094-CB3AE7A0-6C1A-4B96-95E6-05C8A4D1D676Q39440212-FDDC44D9-FB73-486F-A598-9DA0A5AE5A70Q41845586-7DDC3614-C65C-49F8-B6E6-DF9F0F5A766CQ42077718-894E1744-3836-4E61-8BDD-2268AC0CAFD0Q42584937-F0995BC4-0876-4FB1-BCB4-7E48FA30585DQ42679809-CF231A36-9769-4F4C-AD86-B5B986D3C101Q42843362-A1ED1DF4-D725-4A20-83B7-ABF5495CB434Q43088973-163A37DC-FA87-4E24-B30F-6DB9E7330F1AQ44252315-3068DAEF-D9C5-4FF8-BDEB-BAC3F30D88DDQ45161404-4C61270D-F88C-4D37-B965-91E11864B00DQ46200874-B1F17B0D-2F4D-4F5F-9B25-98713765DB19Q46692882-946E9D07-AD3B-4846-9EFD-DC0545578957Q47332919-44D10B8C-2143-4FD9-8DE2-98BF4817631EQ47673180-726A79A2-A735-46F4-8A85-563309D5CA25Q47915469-927F7F0E-1BD9-4481-8EDB-69B87FA0AD8FQ50217126-F4A69481-2317-4F56-916F-3B027072E295Q50495664-9AA6C28A-815F-4A5D-8F85-050DC94AA13AQ51392813-7F749834-1BA2-447E-A251-553A855CFBE8Q51639208-DACC35D5-DBEA-4A16-AA79-941D421E2BF1Q51722272-84A6C6CF-7A2C-4303-AD43-9DFE78A8B77AQ53636388-12D49A40-6931-44F1-B77F-50F4C68B4CDEQ53642992-3E91DE35-151D-4C7B-9774-B767EEB84CA7Q56935450-3BF86C99-71B9-4158-9144-DF0DF7B99587Q82104838-09A7A882-9E78-45B1-8BA0-4CFA6D34ECB2Q83182667-AABCFAFE-2A72-43C7-A8C2-C66FAA660290Q83439976-1FEC15D3-E8AF-49AC-8170-BC1783D3DEE3Q84658896-2D726919-C27E-4560-8DC8-5D30A2CA4AF3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Peter M. Tessier
@ast
Peter M. Tessier
@en
Peter M. Tessier
@es
Peter M. Tessier
@sl
type
label
Peter M. Tessier
@ast
Peter M. Tessier
@en
Peter M. Tessier
@es
Peter M. Tessier
@sl
prefLabel
Peter M. Tessier
@ast
Peter M. Tessier
@en
Peter M. Tessier
@es
Peter M. Tessier
@sl
P1053
I-5730-2013
P106
P1153
7101689432
P21
P31
P3829
P496
0000-0002-3220-007X